Botulinum toxin relieves neuropathic pain not just by blocking signals at the injection site, but by traveling along nerves to reduce pain signaling in the spinal cord.
Peripheral → CentralBoNT travels from the injection site along nerve fibers to the spinal cord, reducing pain signaling at multiple levels of the nervous system
What the researchers found
Botulinum neurotoxins (BoNTs) relieve neuropathic pain through multiple mechanisms that extend far beyond their well-known ability to block neurotransmitter release at the injection site. After peripheral injection, BoNTs are taken up by nerve terminals and reduce the release of pain signaling molecules — glutamate, CGRP, and substance P — decreasing neurogenic inflammation locally.
Critically, BoNTs are also retrogradely transported along nerve fibers to sensory ganglia and central nerve terminals, where they decrease expression of pain-promoting genes and reduce neurotransmitter release from central terminals. This likely reduces central sensitization in the spinal cord. The analgesic effect requires intact TRPV1-expressing pain fibers and substance P/neurokinin-1 receptor signaling.
Engineered BoNTs targeting specific nociceptive pathways are now being developed to improve safety and efficacy for chronic pain treatment.
Why it matters
Neuropathic pain — from conditions like diabetic neuropathy, shingles, and trigeminal neuralgia — is notoriously difficult to treat. While botulinum toxin is already approved for migraines, understanding exactly how it reduces pain could unlock more targeted treatments with fewer side effects. This review maps out the full pathway from injection site to spinal cord, revealing why BoNTs work and how engineered versions could work better.
The numbers in context
BoNT reduces: glutamate, CGRP, substance P release · Acts at: peripheral terminals, sensory ganglia, central terminals · Requires: TRPV1+ afferents, substance P/NK1R signaling
How the study worked
This is a narrative review synthesizing published preclinical and clinical research on the mechanisms by which botulinum neurotoxins produce pain relief. The authors examined evidence from animal models, knockout studies, and clinical observations to map the neurobiological pathways involved.
Who was studied
Review article — synthesizes preclinical (animal model) and clinical evidence on botulinum toxin mechanisms in neuropathic pain
What this study cannot tell us
As a review article, this synthesizes existing research rather than presenting new data. Many of the mechanistic insights come from animal models and may not fully translate to humans. Whether BoNT's central nervous system effects are direct (via transport across synapses) or indirect (secondary to peripheral changes) remains unresolved and controversial.
How to read the evidence
This is a narrative review consolidating evidence from multiple preclinical and clinical studies. While it provides a comprehensive mechanistic framework, it does not present new experimental data, and many findings are from animal models.
When this study was published
Published in 2024, this review reflects the current state of knowledge on botulinum toxin pain mechanisms and includes recent developments in engineered BoNTs.
The bigger picture
Chronic neuropathic pain affects millions and responds poorly to conventional painkillers. Understanding that botulinum toxin works through central nervous system mechanisms — not just local nerve blockade — opens the door to next-generation pain treatments. Engineered BoNTs targeting specific pain pathways represent a frontier in peptide-based therapeutics for chronic pain.
Questions still open
- Does botulinum toxin actually cross synapses to directly affect spinal cord neurons, or are the central effects entirely secondary to peripheral changes?
- How will engineered BoNTs targeting specific nociceptive pathways perform in clinical trials compared to native botulinum toxin?
- Could combination therapy with BoNTs and other pain medications produce synergistic effects in treatment-resistant neuropathic pain?
Common questions
Is botulinum toxin already used for pain treatment?
How is botulinum toxin different from typical painkillers?
Read the original research
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain.
Pharmacology & therapeutics, 259, 108668
Citation
Bagues, Ana; Hu, Jiaxin; Alshanqiti, Ishraq; Chung, Man-Kyo. (2024). Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain.. Pharmacology & therapeutics, 259, 108668. https://doi.org/10.1016/j.pharmthera.2024.108668